84-1048-87　［取扱停止］TACE, CT (TNF-alpha Converting Enzyme) 100ug　T0500-06

特徴

• Beta-amyloid (Ab) deposition in the brain is the hallmark of Alzheimer's Disease (AD).
• To initiate Ab formation, beta-secretase cleaves APP at the N-terminus of Ab to release APPsb (~100kD soluble NT-fragment), and C99, a 12kD CT membrane fragment.
• Alternatively, alpha-secretase cleaves within the Ab to prevent the formation of Ab.
• Cleavage by alpha-secretase produces a soluble N-terminal fragment, APPsa, and a 10kD membrane C-terminal fragment, C83.
• Both C99 and C83 can be further cleaved by gamma-secretase releasing Ab and a nonpathogenic p3 peptide, respectively.
• Recently TACE, a member of the ADAM family (A Disintegrin And Metalloprotease family) protease has been shown to play a central role in a regulated cleavage of human APP.
• Inhibition of TACE affects both APP secretion and Ab formation in cultured cells (1).
• Membrane-bound TNF-a, like APP, is transmembrane protein that can undergo TACE-mediated proteolysis to release the extracellular domain as soluble TNF-a.
• TACE contain an autoinhibitory domain that must be removed for activity, a proteolytic domain, a disintegrin domain, a cysteine-rich domain and a transmembrane domain
• Applications:Suitable for use in ELISA.
• Western Blot, though not tested, may potentially be used as an application.
• Other applications not tested.
• Recommended Dilution:ELISA: 1:10,000-1:100,000 using 50-100ng of control peptide/well.
• See cat# T0500-10A
• Western Blot: 1-10ug/ml using ECL
• Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4°C for short-term only.
• For long-term storage, aliquot and store at -20°C.
• Aliquots are stable for at least 12 months at -20°C.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
• Further dilutions can be made in assay buffer.